Search Constraints

Start Over
Filtering by: Creator/Author Kilroy, Mary Remove constraint Creator/Author: Kilroy, Mary Language English Remove constraint Language: English

Search Results

  • Figure 2 572918348R MRTX1133 Extended Time Point Full Length Blots

    Dataset thumbnail: Figure 2 572918348R MRTX1133 Extended Time Point Full Length Blots
    Type:
    Dataset
    Description/Abstract:
    572918-348-R colorectal cancer organoids were treated with 300nM MRTX1133 for 0, 24, 48, and 72 hours before lysis and loading onto 7.5% SDS-PAGE gels. Gels were transferred to nitrocellulose membranes and cut at the 95kDa and just below the 52 kDa molecular weight (MW) markers. Membranes were then probed for proteins that fell within the MW and evaluated for change in comparison to the 0h control.
    Creator/Author:
    Kilroy, Mary
    Submitter:
    Mary Kilroy
    Date Uploaded:
    05/24/2025
    Date Modified:
    05/24/2025
    License:
    Attribution 4.0 International

  • SNU-407 Combination MTT Excel Files for SynergyFinder+ (Figure 5)

    Dataset thumbnail: SNU-407 Combination MTT Excel Files for SynergyFinder+ (Figure 5)
    Type:
    Dataset
    Description/Abstract:
    SNU-407 cells were treated with a combination of varying concentrations of MRTX1133 with varying concentrations of either afatinib, sapitinib, or pelitinib for 72 hours. Absorbances were normalized to DMSO control for % viability. The attached files were compiled in data format from n=2 data sets (6 data points total for each combination) and uploaded to SynergyFinder+ with % viability chosen as response.
    Creator/Author:
    Kilroy, Mary
    Submitter:
    Mary Kilroy
    Date Uploaded:
    03/07/2025
    Date Modified:
    03/07/2025
    Date Created:
    2024
    License:
    Attribution 4.0 International

  • LS513 Combination MTT Excel Files for SynergyFinder+ (Figure 5)

    Dataset thumbnail: LS513 Combination MTT Excel Files for SynergyFinder+ (Figure 5)
    Type:
    Dataset
    Description/Abstract:
    LS513 cells were treated with a combination of varying concentrations of MRTX1133 with varying concentrations of either afatinib, sapitinib, or pelitinib for 72 hours. Absorbances were normalized to DMSO control for % viability. The attached files were compiled in data format from n=2 data sets (6 data points total for each combination) and uploaded to SynergyFinder+ with % viability chosen as response.
    Creator/Author:
    Kilroy, Mary
    Submitter:
    Mary Kilroy
    Date Uploaded:
    03/07/2025
    Date Modified:
    03/07/2025
    Date Created:
    2024
    License:
    Attribution 4.0 International